newsfilter
← Latest News
Business Wire·

Spectrum Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Eflapegrastim BLA under FDA review; PDUFA date September 9, 2022 FDA completes re-inspection of drug substance manufacturing facility for eflapegrastim Poziotinib NDA under FDA review with ODAC meeting on September 22, 2022 Management to host w